NEW YORK (GenomeWeb) – MNG Laboratories announced today that that it has signed a deal to make Pronto Diagnostics the exclusive distributor of its neurogenetic clinical RNA sequencing services in Israel.
The deal includes MNG's complete transcriptome sequencing service; gene-specific RNA sequencing, which includes up to five genes for investigating previously identified variants of unknown significance; and panel-specific RNA sequencing, which analyzes the expression of all genes in a next-generation sequencing panel that was ordered at the same time.
Tel Aviv-based Pronto will offer the services in Israel, with all testing performed by MNG at its Atlanta lab. Clinical reports will be delivered to customers within two to four weeks.
Additional terms of the deal were not disclosed.
"This partnership with Pronto is an important addition to the expansion strategy at MNG to bring our portfolio of world class neurogenetic testing to the global rare disease diagnostic market," Humberto Huerta, senior director of business development at MNG, said in a statement.